Ulrike Dirmeier

1.1k total citations
14 papers, 832 citations indexed

About

Ulrike Dirmeier is a scholar working on Immunology, Oncology and Epidemiology. According to data from OpenAlex, Ulrike Dirmeier has authored 14 papers receiving a total of 832 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Oncology and 4 papers in Epidemiology. Recurrent topics in Ulrike Dirmeier's work include Virus-based gene therapy research (4 papers), Immunotherapy and Immune Responses (4 papers) and Viral-associated cancers and disorders (3 papers). Ulrike Dirmeier is often cited by papers focused on Virus-based gene therapy research (4 papers), Immunotherapy and Immune Responses (4 papers) and Viral-associated cancers and disorders (3 papers). Ulrike Dirmeier collaborates with scholars based in United States, Germany and Switzerland. Ulrike Dirmeier's co-authors include Wolfgang Hammerschmidt, Ellen Kilger, Diana Dudziak, Georg W. Bornkamm, Falk Nimmerjahn, Mark L. Sandberg, G. Reisbach, Bernhard Neuhierl, Andreas Rosenwald and Uta Behrends and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Ulrike Dirmeier

14 papers receiving 804 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ulrike Dirmeier United States 13 329 305 294 205 137 14 832
Yanxing Yu United States 11 410 1.2× 552 1.8× 202 0.7× 395 1.9× 98 0.7× 12 946
Helmut Bannert Germany 12 176 0.5× 370 1.2× 269 0.9× 271 1.3× 121 0.9× 17 795
David N. Everly United States 14 335 1.0× 364 1.2× 388 1.3× 482 2.4× 58 0.4× 18 1.0k
Liudmila Matskova Sweden 19 188 0.6× 284 0.9× 510 1.7× 118 0.6× 141 1.0× 42 954
Alexander M. Price United States 16 187 0.6× 393 1.3× 352 1.2× 201 1.0× 129 0.9× 21 772
Sanae Nakayama Japan 17 145 0.4× 392 1.3× 285 1.0× 430 2.1× 69 0.5× 22 775
Satoko Iwahori Japan 21 134 0.4× 442 1.4× 366 1.2× 458 2.2× 58 0.4× 31 922
Tadamasa Ooka France 19 186 0.6× 568 1.9× 149 0.5× 320 1.6× 84 0.6× 28 833
Akhilesh K. Singh United States 16 556 1.7× 132 0.4× 261 0.9× 219 1.1× 44 0.3× 20 950
Gretchen L. Bentz United States 18 582 1.8× 441 1.4× 538 1.8× 735 3.6× 259 1.9× 20 1.5k

Countries citing papers authored by Ulrike Dirmeier

Since Specialization
Citations

This map shows the geographic impact of Ulrike Dirmeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrike Dirmeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrike Dirmeier more than expected).

Fields of papers citing papers by Ulrike Dirmeier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrike Dirmeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrike Dirmeier. The network helps show where Ulrike Dirmeier may publish in the future.

Co-authorship network of co-authors of Ulrike Dirmeier

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrike Dirmeier. A scholar is included among the top collaborators of Ulrike Dirmeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrike Dirmeier. Ulrike Dirmeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Capelle, Martinus A.H., et al.. (2018). Stability and suitability for storage and distribution of Ad26.ZEBOV/MVA-BN®-Filo heterologous prime-boost Ebola vaccine. European Journal of Pharmaceutics and Biopharmaceutics. 129. 215–221. 21 indexed citations
2.
Heery, Christopher R., Claudia Palena, Sheri McMahon, et al.. (2017). Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. Clinical Cancer Research. 23(22). 6833–6845. 51 indexed citations
3.
Schweneker, Marc, Andrea Laimbacher, Gert Zimmer, et al.. (2017). Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles. Journal of Virology. 91(11). 17 indexed citations
4.
5.
Heery, Christopher R., Renee N. Donahue, Lauren M. Lepone, et al.. (2015). Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P132–P132. 3 indexed citations
6.
Wennier, Sonia, Kay Brinkmann, Ulrike Dirmeier, et al.. (2013). A Novel Naturally Occurring Tandem Promoter in Modified Vaccinia Virus Ankara Drives Very Early Gene Expression and Potent Immune Responses. PLoS ONE. 8(8). e73511–e73511. 24 indexed citations
7.
Rountree, Ryan B., Stefanie Mandl, Kay Brinkmann, et al.. (2011). Exosome Targeting of Tumor Antigens Expressed by Cancer Vaccines Can Improve Antigen Immunogenicity and Therapeutic Efficacy. Cancer Research. 71(15). 5235–5244. 130 indexed citations
8.
Mandl, Stefanie, Ryan B. Rountree, Ulrike Dirmeier, et al.. (2011). Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Cancer Immunology Immunotherapy. 61(1). 19–29. 22 indexed citations
9.
10.
Dirmeier, Ulrike, Reinhard Hoffmann, Ellen Kilger, et al.. (2005). Latent membrane protein 1 of Epstein–Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene. 24(10). 1711–1717. 117 indexed citations
11.
Nimmerjahn, Falk, Diana Dudziak, Ulrike Dirmeier, et al.. (2004). Active NF-κB signalling is a prerequisite for influenza virus infection. Journal of General Virology. 85(8). 2347–2356. 186 indexed citations
12.
Dirmeier, Ulrike, Bernhard Neuhierl, Ellen Kilger, et al.. (2003). Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus.. PubMed. 63(11). 2982–9. 116 indexed citations
13.
Dudziak, Diana, Arnd Kieser, Ulrike Dirmeier, et al.. (2003). Latent Membrane Protein 1 of Epstein-Barr Virus Induces CD83 by the NF-κB Signaling Pathway. Journal of Virology. 77(15). 8290–8298. 40 indexed citations
14.
Dirmeier, Ulrike, et al.. (2000). The Synechococcus Strain PCC 7942 glnN Product (Glutamine Synthetase III) Helps Recovery from Prolonged Nitrogen Chlorosis. Journal of Bacteriology. 182(19). 5615–5619. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yanxing Yu Breakdown of academic impact, for papers by Helmut Bannert Breakdown of academic impact, for papers by David N. Everly Breakdown of academic impact, for papers by Liudmila Matskova Breakdown of academic impact, for papers by Alexander M. Price Breakdown of academic impact, for papers by Sanae Nakayama Breakdown of academic impact, for papers by Satoko Iwahori Breakdown of academic impact, for papers by Tadamasa Ooka Breakdown of academic impact, for papers by Akhilesh K. Singh Breakdown of academic impact, for papers by Gretchen L. Bentz
Rankless by CCL
2026